You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

TECFIDERA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tecfidera patents expire, and what generic alternatives are available?

Tecfidera is a drug marketed by Biogen Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-eight patent family members in twenty-nine countries.

The generic ingredient in TECFIDERA is dimethyl fumarate. There are seventy-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the dimethyl fumarate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tecfidera

A generic version of TECFIDERA was approved as dimethyl fumarate by MYLAN on August 17th, 2020.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TECFIDERA?
  • What are the global sales for TECFIDERA?
  • What is Average Wholesale Price for TECFIDERA?
Drug patent expirations by year for TECFIDERA
Drug Prices for TECFIDERA

See drug prices for TECFIDERA

Recent Clinical Trials for TECFIDERA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 2
Banner Life Sciences LLCPhase 1
Fondation Ophtalmologique Adolphe de RothschildPhase 4

See all TECFIDERA clinical trials

Paragraph IV (Patent) Challenges for TECFIDERA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TECFIDERA Delayed-release Capsules dimethyl fumarate 120 mg and 240 mg 204063 29 2017-03-27

US Patents and Regulatory Information for TECFIDERA

TECFIDERA is protected by nine US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 AB RX Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TECFIDERA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-001 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
Biogen Inc TECFIDERA dimethyl fumarate CAPSULE, DELAYED RELEASE;ORAL 204063-002 Mar 27, 2013 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for TECFIDERA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Almirall S.A Skilarence dimethyl fumarate EMEA/H/C/002157
Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.
Authorised no no no 2017-06-23
Biogen Netherlands B.V. Tecfidera dimethyl fumarate EMEA/H/C/002601
Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Authorised no no no 2014-01-30
Mylan Ireland Limited Dimethyl fumarate Mylan dimethyl fumarate EMEA/H/C/005956
Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Authorised yes no no 2022-05-13
Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. Dimethyl fumarate Polpharma dimethyl fumarate EMEA/H/C/005955
Dimethyl fumarate Polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Authorised yes no no 2022-05-13
Laboratorios Lesvi S.L. Dimethyl fumarate Neuraxpharm dimethyl fumarate EMEA/H/C/006039
Dimethyl fumarate Neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
Authorised yes no no 2022-05-13
Teva GmbH Dimethyl fumarate Teva dimethyl fumarate EMEA/H/C/005963
Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Authorised yes no no 2022-12-12
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for TECFIDERA

See the table below for patents covering TECFIDERA around the world.

Country Patent Number Title Estimated Expiration
Spain 2424022 ⤷  Subscribe
European Patent Office 3116536 FUMARATE DE DIMÉTHYLE ET RÉGIMES DE VACCINATION (DIMETHYL FUMARATE AND VACCINATION REGIMENS) ⤷  Subscribe
Austria 242633 ⤷  Subscribe
Brazil 9914606 ⤷  Subscribe
Hong Kong 1139204 COMPOSITIONS AND USES FOR TREATING MULTIPLE SCLEROSIS ⤷  Subscribe
China 113368092 治疗多发性硬化的方法 (Methods of treating multiple sclerosis) ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TECFIDERA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1131065 92488 Luxembourg ⤷  Subscribe PRODUCT NAME: DIMETHYL FUMARATE. FIRST REGISTRATION: 20140130
0230742 2001C/040 Belgium ⤷  Subscribe PRODUCT NAME: MONOHYDRATE DU CHLORHYDRATE DE N,N-DIMETHYL-1-4-CHLOROPHENYL)CYCLOBUTYL-3-METHYLBUTYLAMINE ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT; NAT. REGISTRTION NO/DATE: 479 IS 52 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113
2137537 122014000069 Germany ⤷  Subscribe PRODUCT NAME: DIMETHYLFUMARAT; REGISTRATION NO/DATE: EU/1/13/837/001-002 20140130
2653873 LUC00294 Luxembourg ⤷  Subscribe PRODUCT NAME: DIMETHYL FUMARATE (TECFIDERA); AUTHORISATION NUMBER AND DATE: EU/1/13/837/001-002 20140203
0526708 SPC/GB02/030 United Kingdom ⤷  Subscribe PRODUCT NAME: BOSENTAN 4-(1,1-DIMETHYLETHYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2(PYRIMIDIN-2-YL)PYRIMIDIN-4-YL)BENZENESULFONAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
2653873 2023C/501 Belgium ⤷  Subscribe PRODUCT NAME: FUMARATE DE DIMETHYLE; AUTHORISATION NUMBER AND DATE: EU/1/13/837 20140203
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

TECFIDERA Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Tecfidera

Introduction

Tecfidera, also known as dimethyl fumarate, is a pivotal drug in the treatment of multiple sclerosis (MS), particularly for patients with relapsing forms of the disease. Developed and marketed by Biogen, Tecfidera has had a significant impact on the MS treatment landscape since its launch. Here, we delve into the market dynamics and financial trajectory of Tecfidera.

Launch and Initial Market Impact

Tecfidera was launched in 2013 and quickly gained traction due to its perceived greater efficacy compared to other oral therapies available at the time, such as Aubagio[1].

  • The drug's launch was highly anticipated by physicians, leading to a rapid uptake and a steep growth trajectory. This surge in adoption was partly due to physicians "warehousing" patients in anticipation of the drug's availability.

Market Growth and Dominance

In the early years following its launch, Tecfidera exhibited strong growth, particularly in the EU5 markets (Germany, UK, Italy, Spain, and France) and the US. The drug's growth mirrored the decline in injectable MS therapies, indicating a shift in treatment preferences towards oral medications[1].

  • By 2015, Tecfidera had established itself as a leading oral therapy for MS, with its growth trajectory sustained by continued confidence from physicians in various markets.

Economic Value and Social Impact

Tecfidera, along with other MS therapies like Avonex and Tysabri, has generated significant economic and social value. A study indicated that these therapies provided $46.2 billion in total value to consumers, with a substantial portion of this value accruing to individuals without MS due to the "peace of mind" factor[3].

  • The use of Tecfidera has been associated with reduced relapse rates and disability progression, although the exact income and medical cost effects were conservatively estimated based on Avonex data due to limited sample sizes[3].

Competitive Landscape

The MS treatment market is highly competitive, with several immunomodulators, immunosuppressants, and interferons available. Tecfidera has been a key player in the immunomodulators segment, which dominates the U.S. MS drugs market[4].

  • Biogen, the manufacturer of Tecfidera, has maintained a significant market share due to the strong sales of its MS products, including Tecfidera and Vumerity[4].

Financial Performance

Tecfidera has been a major revenue generator for Biogen. However, in recent years, the drug has faced significant challenges:

  • Generic Competition: The entry of generic versions of Tecfidera has led to a decline in its revenue. In the fourth quarter of 2023, Tecfidera's revenue dropped by 17.8% to $244.3 million due to generic competition[5].
  • Market Share and Revenue: Despite its initial success, Tecfidera's market share and revenue have been impacted by the launch of generics and other competitive therapies. Biogen's overall MS revenue declined by 8% in the fourth quarter of 2023[5].

Future Outlook

Biogen is navigating the challenges posed by generic competition and patent expirations by focusing on new product launches and diversifying its portfolio:

  • New Product Launches: Biogen is banking on new approvals, such as Skyclarys for Friedreich’s ataxia and Leqembi for Alzheimer’s disease, to offset the decline in MS drug sales. These new products are expected to play a significant role in the company's revenue growth strategy over the next decade[5].
  • Market Projections: The U.S. MS drugs market, which includes Tecfidera, is projected to grow from $9.45 billion in 2023 to $14.10 billion by 2030, with a CAGR of 5.9%. However, the immunomodulators segment, where Tecfidera resides, will face continued competition and potential erosion from generics[4].

Challenges and Opportunities

Generic Entry

The entry of generic versions of Tecfidera poses a significant challenge to its revenue. Biogen expects further declines in Tecfidera revenue due to generic competition in both the U.S. and EU markets[2].

Regulatory and Market Dynamics

The ongoing challenges to Tecfidera's market protection and the potential entry of generics in the EU as early as the first half of 2022 add uncertainty to its financial trajectory[2].

Diversification and New Launches

Biogen's strategy to reposition itself away from its legacy MS franchise towards new products offers opportunities for growth. The success of new launches will be crucial in mitigating the impact of declining MS drug sales[5].

Key Takeaways

  • Rapid Uptake: Tecfidera quickly gained market share upon its launch due to its perceived efficacy.
  • Economic Value: The drug has generated significant economic and social value, including reduced relapse rates and disability progression.
  • Generic Competition: The entry of generics has significantly impacted Tecfidera's revenue.
  • Future Outlook: Biogen is diversifying its portfolio to offset declines in MS drug sales, focusing on new product launches.

FAQs

What was the initial market impact of Tecfidera upon its launch?

Tecfidera stormed the market upon its launch in 2013, driven by high anticipation and perceived greater efficacy compared to other oral therapies available at the time.

How has generic competition affected Tecfidera's revenue?

Generic competition has led to a significant decline in Tecfidera's revenue, with a 17.8% drop in the fourth quarter of 2023.

What is the projected growth of the U.S. MS drugs market?

The U.S. MS drugs market is projected to grow from $9.45 billion in 2023 to $14.10 billion by 2030, with a CAGR of 5.9%.

How is Biogen addressing the decline in MS drug sales?

Biogen is focusing on new product launches and diversifying its portfolio to offset the decline in MS drug sales, with a strategy to reposition itself away from its legacy MS franchise.

What are the key challenges facing Tecfidera in the current market?

The key challenges include generic competition, regulatory uncertainties, and the ongoing erosion of market protection.

Sources

  1. Ipsos Healthcare: Multiple Sclerosis: The Evolving Competitive Landscape, the Future Challenges and the Opportunities.
  2. Biogen Investors: Biogen Reports Fourth Quarter and Full Year 2021 Results.
  3. American Journal of Managed Care: Reconsidering the Economic Value of Multiple Sclerosis Therapies.
  4. Fortune Business Insights: U.S. Multiple Sclerosis Drugs Market Research Report [2030].
  5. BioSpace: Biogen Misses Q4 Revenue Estimates on Aduhelm Costs, Lower MS Drug Sales.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.